Maxigen Biotech Inc. Maxigen Biotech Inc.

Maxigen Biotech Inc.

1783

Rank in Stocks #19726
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development,... Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
Share Price
$1.09
Last synced: 2026-11-13
Market Cap
$98.01M
Change (1 day)
0.36%
Change (1 year)
-23.32%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Maxigen Biotech Inc. (1783)
Operating Margin as of November 2026 TTM: 32.83%
According to Maxigen Biotech Inc.'s latest financial reports, its current operating margin (TTM) is 32.83%. At the end of 2025 the company had an operating margin of 32.17%.
Operating Margin history for Maxigen Biotech Inc. from 2009 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 32.83% 2.05%
2025 32.17% 12.64%
2024 28.56% 18.56%
2023 24.09% -14.64%
2022 28.22% 43.47%
2021 19.67% 17.08%
2020 16.80% -0.18%
2019 16.83% 55.98%
2018 10.79% 119.31%
2017 4.92% -246.43%
2016 -3.36% -85.49%
2015 -23.15% 98.88%
2014 -11.64% 660.78%
2013 -1.53% -68.19%
2012 -4.81% -79.34%
2011 -23.28% 29.77%
2010 -17.94% -542.96%
2009 4.05% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
28.37% -99.14%
US
12.36% -99.62%
FR
11.78% -99.64%
US
31.11% -99.05%
JP
10.21% -99.69%
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Maxigen Biotech Inc.'s operating margin

What is Maxigen Biotech Inc.'s operating margin?

Maxigen Biotech Inc.'s operating margin is 32.83%, as of Nov 2026.

What was Maxigen Biotech Inc.'s operating margin in 2025?

In 2025, Maxigen Biotech Inc.'s operating margin was 32.17%, compared with 28.56% in 2024.

How has Maxigen Biotech Inc.'s operating margin changed since 2020?

From 2020 to 2025, Maxigen Biotech Inc.'s operating margin was highest in 2025 (32.17%) and lowest in 2020 (16.80%).

How does Maxigen Biotech Inc.'s operating margin compare with similar companies?

Maxigen Biotech Inc.'s operating margin (32.83%) is higher than that of all 5 similar companies listed above. The highest among them is HOYA Corporation, with 31.11%.